Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients

June 23, 2011 updated by: Ventria Bioscience

A Phase III Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients

The purpose of the study is to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

340

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

48 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All patients must meet all of the inclusion criteria listed below at the time of enrollment.

    1. Male and female patients 50 years of age and older.
    2. Resident of a participating long term care facility.
    3. Able to consume 30 mL of liquid solution two time per day by mouth or enteral feeding tube.
    4. Patient has had no antibiotics in the 4 weeks preceding enrollment in the study.
    5. Patient has been started on a broad spectrum antibiotic(s) for an infection other than gastroenteritis.
    6. Patient has a life expectancy greater than 6 months.
    7. Patient or health care agent is able and willing to sign a written informed consent.
    8. Patient or caregiver is able and willing to complete diary of daily bowel movement information (number, formed or unformed, time) during any portion of the 8 week study.

Exclusion Criteria:

  1. Patient has an ileostomy.
  2. Patient has a prior history of major gastrointestinal surgery such as partial small bowel or colon resection or gastric bypass.
  3. Patient has a history of inflammatory bowel disease.
  4. Patient has a history of chronic diarrhea associated with irritable bowel syndrome or other etiologies.
  5. Patient has a history of severe constipation requiring use of enemas or disimpaction within 30 days prior to enrollment.
  6. Patient has signs or symptoms of C. difficile infection including diarrhea.
  7. Patient has signs or symptoms of acute or chronic diarrhea.
  8. Patient has known sensitivity or allergy to rice or rice products.
  9. Patient has significant medical problems which in the judgment of the principal investigator or medical monitor may interfere with participation in the study.
  10. Patient is not receiving an antibiotic regimen consisting of a broad spectrum antibiotic.
  11. Patient has participated in an investigational study using an investigational product within 30 days of randomization.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ven100
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Reduction in the number of days of antibiotic associated diarrhea during the treatment period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Ning Huang, Ph.D., Ventria Bioscience

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2011

Primary Completion (Anticipated)

September 1, 2013

Study Completion (Anticipated)

March 1, 2014

Study Registration Dates

First Submitted

June 21, 2011

First Submitted That Met QC Criteria

June 23, 2011

First Posted (Estimate)

June 27, 2011

Study Record Updates

Last Update Posted (Estimate)

June 27, 2011

Last Update Submitted That Met QC Criteria

June 23, 2011

Last Verified

June 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

  • VB-Ven100-2011-01
  • R44AG037211 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diarrhea

Clinical Trials on Lactoferrin

3
Subscribe